Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.

Postgraduate medicine

Volumn 125, Issue 3, 2013, Pages 145-154

  Cook, William ^a   Bryzinski, Brian ^b   Slater, Jill ^b   Frederich, Robert ^b   Allen, Elsie ^b  

^a ASTRAZENECA   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; GLIBENCLAMIDE; METFORMIN; SAXAGLIPTIN;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADAMANTANE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 84882289422     PISSN: None     EISSN: 19419260     Source Type: None    
DOI: 10.3810/pgm.2013.05.2657     Document Type: Article

References (0)